Equity Research Pharmaceutical Preparations

Should You Buy Assembly Biosciences, Inc. Stock in 2026?

By CirclFi Research Team · · 9/13 models active

According to the CirclFi Deep Alpha Valuation Engine, Assembly Biosciences, Inc. (ASMB) carries a solid Quality of Company rating of 5.5/10. Trading at $25.06, our multi-model framework evaluates whether the company's financial profile offers a favorable risk-reward setup.

The short answer: 2 of 9 CirclFi valuation models project upside for Assembly Biosciences, Inc. (ASMB) at $25.06 — the model consensus leans bearish, with a Quality Score of 5.5/10 and Value-Trap risk of 38/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.

Key Takeaways

  • 7 of 9 models suggest overvaluation — majority bearish
  • Quality Score: 5.5/10 — Moderate — mixed signals
  • Value Trap Risk: 38/100 — Low — manageable risk
  • Fair Value Range: $1.34 – $25.93 (1832% spread)

Bullish Models

2 / 9

Bearish Models

7 / 9

Quality Score

5.5 /10

Moderate — mixed signals

Value Trap Risk

38 /100
Low

Low — manageable risk

Model Consensus

9 /13
Active Models

Avg. confidence: 27%

Investment Thesis

The Bull Case

Target: $25.93 (+3.5% upside)

  • Industry tailwind: licensing and M&A optionality could provide meaningful support for Assembly Biosciences, Inc.'s revenue and margin trajectory in the Pharmaceutical Preparations space.

The Bear Case

Target: $1.34 (-94.6%)

  • According to the CirclFi Deep Alpha Valuation Engine, the ML Residual Income model sees the stock as overvalued with a fair value of $1.34 (-94.6%), suggesting that the market price embeds overly optimistic growth assumptions.
  • According to the CirclFi Deep Alpha Valuation Engine, model disagreement is high with a +98.1% spread between the most bullish and bearish models, signaling elevated analytical uncertainty.
  • Industry headwind: generic/biosimilar competition represents a meaningful risk for Assembly Biosciences, Inc. and its Pharmaceutical Preparations peers.

Peer Benchmarking

AMPH Amphastar Pharmaceut
10.0
AZN AstraZeneca PLC
10.0
CPRX Catalyst Pharmaceuti
10.0
HRMY Harmony Biosciences
10.0
NVO Novo Nordisk A/S
10.0

See full Pharmaceutical Preparations rankings →

Valuation Divergence

Spread

1832%

Fair Value Range

$1.34 – $25.93

A 1832% spread signals high uncertainty. The investment outcome depends heavily on which scenario plays out.

Most Bullish

PWERM

$25.93 (+3.5%)

Most Bearish

ML-RIV

$1.34 (-94.6%)

Key Risk Factors

Model Disagreement

1832% spread signals high variance in projections.

Bearish Consensus

7/9 models suggest overvaluation.

Macro/Sector Risk

Pharmaceutical Preparations headwinds could affect earnings trajectory.

Model Limitations

Backward-looking models cannot predict disruptions.

Want the full 13-model breakdown?

See every fair value, confidence score, and value trap analysis.

View ASMB Data Page →

The Bottom Line

Our valuation engine sends a clear cautionary signal on Assembly Biosciences, Inc. at $25.06. 7/9 models flag overvaluation, composite fair value sits at $10.20 (-59.3%), and the risk-reward profile appears unfavorable. Quality at 5.5/10 adds to the concern. This is a stock where patience — or avoidance — may be the optimal strategy.

These are quantitative model outputs, not investment recommendations. Assembly Biosciences, Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →

Frequently Asked Questions

Should I buy ASMB stock right now?

Based on CirclFi's multi-model analysis, 2 of 9 models see upside for ASMB at $25.06. The models are divided, which means the investment case depends heavily on your assumptions about Assembly Biosciences, Inc.'s future. This is not a buy recommendation — see our full disclaimer.

What are the biggest risks of investing in Assembly Biosciences, Inc.?

Key risks include: wide model disagreement (1832% spread), signaling high uncertainty; general market and sector-specific risks affecting Pharmaceutical Preparations companies. Always diversify and consult a financial advisor.

How does ASMB compare to its competitors?

Among Pharmaceutical Preparations peers, ASMB holds a Quality Score of 5.5/10. Comparable companies include AMPH (QOC 10.0), AZN (QOC 10.0), CPRX (QOC 10.0). The relative ranking helps investors identify whether ASMB offers better fundamental quality than alternatives in the same sector.

Is ASMB a good long-term investment?

Long-term investment potential depends on fundamental quality and sustainable competitive advantages. ASMB's Quality Score of 5.5/10 suggests moderate fundamentals — not a clear long-term hold without further research into growth catalysts. Check our full data page for all 13 model estimates.

What price should I buy ASMB at?

CirclFi does not provide target buy prices or price alerts. However, our 9 active models produce fair value estimates ranging from $1.34 to $25.93. At $25.06, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.

Want the complete picture?

See all 13 model estimates, confidence scores, and the full valuation table for ASMB.

View ASMB Data Page Full Terminal — $39/mo

Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →